CJC-1295 and sermorelin are often grouped together because both interact with growth-hormone-releasing pathways, but they are not interchangeable. Their molecular characteristics, clinical histories, evidence and regulatory status differ. This comparison is intended to help patients understand those distinctions before discussing treatment with a physician.
CJC-1295 is a synthetic growth-hormone-releasing hormone analogue studied for its ability to influence growth hormone and IGF-1. It is not an FDA-approved drug. FDA has identified limited clinical data and potential safety concerns for compounded CJC-1295, including immunogenicity and peptide-related impurities, and has noted reports including increased heart rate and systemic vasodilatory reactions.
Sermorelin is a growth-hormone-releasing hormone analogue with a different clinical and regulatory history. Historical FDA-approved sermorelin products existed for pediatric diagnostic/treatment uses, but those products were discontinued and their approvals were later withdrawn. Current use should therefore not be described as though sermorelin were presently FDA approved for anti-aging, body composition or routine adult wellness.
There is not enough high-quality evidence to make a blanket claim that one is “better” for general wellness, anti-aging, muscle gain or fat loss. The more important questions are whether there is a medically appropriate indication, whether an approved treatment exists, what evidence supports the proposed use and what risks apply to the individual patient.
See our dedicated CJC-1295 & Ipamorelin guide, Sermorelin Therapy Los Angeles, Peptide Safety & Side Effects, and the main Peptide Therapy Los Angeles resource.
No. They are distinct molecules with different structures, pharmacologic characteristics and regulatory histories.
No. CJC-1295 is not an FDA-approved drug.
No. It should not be marketed as an FDA-approved anti-aging treatment.
Written and medically reviewed by David Nazarian, MD — Board Certified in Internal Medicine. This page is educational and does not recommend an unapproved drug for an individual patient.
